Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 13 of the 30 sources its claims cite were checked for support.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
CoChat Summary
TL;DR
In a single-arm trial, fecal microbiota transplantation (FMT) from anti–PD-1 responders plus pembrolizumab was well tolerated and produced clinical benefit in 6 of 15 evaluable patients with PD-1–refractory melanoma. Responders showed donor microbiome implantation, increased CD8+ T cell activation, and reduced IL-8–expressing myeloid cells.
Key findings
- Among 15 evaluable patients, objective responses occurred in 3 (20%: one complete response, two partial responses), and durable stable disease lasting >12 months occurred in another 3 (20%), for clinical benefit in 6 of 15. Median progression-free survival and overall survival were 3.0 and 7.0 months overall, and 14.0 and 14.0 months in the six patients with disease control.
- FMT caused durable gut microbiota perturbation; responders’ microbiota shifted toward donor composition, whereas nonresponders were heterogeneous. Responders also had greater donor bacteria–specific IgG responses and enrichment of taxa previously linked to anti–PD-1 response, including Firmicutes and Actinobacteria, with decreases in Bacteroidetes.
- Responders showed higher post-treatment CD56+CD8+ T cells, increased CD8+ T cell activation/differentiation markers, and more granzyme B–expressing MAIT cells. Tumor single-cell RNA sequencing showed fewer myeloid cells and regulatory T cells in responders, with lower myeloid CXCL8/IL-8 and SPP1 expression.
- Serum profiling showed responders had decreased circulating CCL2, CXCL8/IL-8, IL-18, IL-12p70, and IFN-γ, and increased IL-21, CXCL13, type II cytokines, and TNF-family cytokines. Metabolomic/lipidomic changes included more efficient primary-to-secondary bile acid conversion and altered triacylglycerol/monoacylglycerol/diacylglycerol levels. A transkingdom network of 371 nodes and 819 edges linked microbial taxa to host metabolomic and proteomic features.
Methods
- Single-arm clinical trial (NCT03341143) in patients with metastatic melanoma primary refractory to anti–PD-1. Sixteen patients were enrolled; 15 received colonoscopic FMT from seven anti–PD-1 responder donors plus pembrolizumab and were evaluable for response.
- Serial blood and stool sampling was performed, with infectious screening for 32 agents before FMT. Response was assessed by RECIST v1.1 every 12 weeks.
- Analyses included shotgun metagenomic sequencing of 223 fecal samples from recipients and donors, multiparameter flow cytometry of PBMCs, single-cell RNA sequencing of 64,340 CD45+ cells from 17 tumor samples, serum cytokine/chemokine profiling, metabolomics/lipidomics, and transkingdom network analysis.
Limitations
- The paper states that findings are preliminary and warrant evaluation in a larger randomized clinical trial; it also notes that insufficient tumor tissue was available to assess tumor mutation burden, PD-L1 expression, or IFN-γ gene expression signature as predictors of outcome.
- The text makes evident that the study is small and single-arm, limiting causal inference and comparison with standard-of-care outcomes; some analyses, such as the speed of microbiome change, did not reach statistical significance, which the authors attribute to limited sample size.
- The text also makes evident heterogeneity in nonresponders’ donor microbiota implantation and notes that nonresponse may reflect patient immunodeficiency, lack of tumor immunogenicity, absence of necessary taxa in the FMT, or failure of FMT implantation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the gut microbiome is a major tumor-extrinsic regulator of responses to anti–PD-1 (6–9).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [6] Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G, Eur. J. Immunol 45, 17– 31 (2015). 25328099 sourceExperimental — accuracy not yet measured
In 'The commensal microbiota controls the response to cancer therapy' our copy confirms that the gut microbiota modulates responses to cancer immunotherapy, chemotherapy, TBI and adoptive T-cell transfer (via myeloid-cell conditioning; see also Fig. 2 legend in Concluding remarks). But for checkpoint blockade the paper states only a hypothesis: after noting progress with anti-CTLA-4/anti-PD-1 antibodies [107], it says the data 'suggest the possibility that the microbiota may also modulate the clinical effectiveness of this new class of anticancer drugs.' The citing sentence therefore presents as an established, major regulator of anti-PD-1 responses what this source explicitly hedges as a suggested possibility, and no anti-PD-1 microbiome experiment is reported in our copy. (LLM, conf=0.78)
- Not checked yetcites [7] Finlay BB, Nat. Rev. Immunol 20, 522– 528 (2020). 32661409 source
- Partly supportedcites [8] Goldszmid RS, Cancer Immunol. Res 3, 103– 109 (2015). 25660553 PMC4324508 sourceExperimental — accuracy not yet measured
In 'Impact of commensal microbiota on cancer therapy' our copy states that 'The gut microbiota influences the response to cancer immunotherapy and chemotherapy by affecting the differentiation and functions of myeloid cells in the tumor microenvironment', and documents microbiota/antibiotic effects on CpG-ODN plus anti-IL10R, cyclophosphamide, oxaliplatin, TBI and adoptive CD8+ T-cell transfer — so the tumor-extrinsic, myeloid-priming part of the claim is supported. However, PD-1 appears only in 'Clinical perspectives' as one of the successful checkpoint approaches ('inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1/2'), with no linkage to microbiota; the paper instead only speculates that 'the variable response to cancer therapy observed in patients may be in part due to different microbiota composition'. Searches for 'anti-PD-1', checkpoint-blockade response and microbiota-control-of-checkpoint-efficacy returned no passage tying the microbiome to anti–PD-1 outcomes, so the specific anti–PD-1 qualifier of the claim is not supported by this source (it likely rests on the other references in the cluster 6–9). (LLM, conf=0.72)
- Could not verifycites [9] Zarour HM, Clin. Cancer Res 22, 1856– 1864 (2016). 27084739 PMC4872712 sourceExperimental — accuracy not yet measured
Our copy of Zarour (2016) is complete and discusses tumor-extrinsic drivers of anti-PD-1 response only in terms of the tumor microenvironment: soluble mediators (IL-10, IDO, VEGF-A, adenosine/A2aR, CSF-1R), suppressive cells (Tregs, TAM/MDSC), metabolic checkpoints (hypoxia/HIF-1α) and mutational/neoepitope burden correlating with clinical response (Therapeutic Strategies section). No passage mentions the gut microbiome, microbiota, or antibiotics; searches for 'gut microbiome/microbiota regulates response to anti-PD-1', 'microbiota composition antibiotic impact immunotherapy efficacy tumor-extrinsic', and 'bacterial composition fecal transplant' returned only TME-related and reference-list passages. The paper therefore neither supports nor contradicts the attributed claim. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that successful implantation and mucosal trans-location of the transplanted bacteria, known to induce an IgG response against commensal bacteria, may preferentially occur in Rs (18).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant induces persistent perturbation of recipients’ gut microbiome
What the sources say
- Supportedcites [18] Zeng MY, Immunity 44, 647– 658 (2016). 26944199 PMC4794373 source
The clause the citation is offered for is the background fact that mucosal translocation of gut bacteria is what induces an IgG response against commensal bacteria; the 'preferentially occur in Rs' inference is the citing authors' own conclusion from their FMT data and is not attributed content. Our copy states exactly that mechanism: the Results section 'Homeostatic Induction of Systemic IgG to Gram-Negative Symbiotic Bacteria' concludes that a selective group of gram-negative symbiotic bacteria breach the intestinal epithelial barrier and disseminate systemically to induce IgG, backed by detection of bacterial 16S rRNA in spleens/MLNs and Enterobacteriaceae being the predominant translocated families, and the Introduction/Discussion describe translocation-driven systemic IgG to symbiotic (commensal) bacteria. The only slippage is contextual — Zeng et al. studied resident murine symbionts under homeostatic conditions, not donor/transplanted bacteria or FMT responders — but the mechanism attributed to this source is stated there. (LLM, conf=0.82)
hedgedstates a possible causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“administration of certain gut commensals or fecal microbiota transplantation (FMT) promotes anti–PD-1 efficacy in melanoma-bearing mice (10–12).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s FMT experiments (Fig. 4G–I; page unavailable) report reduced tumor growth and improved response to anti-PD-L1 therapy in mice receiving stool from patients who responded to anti-PD-1, compared with stool from nonresponders. Our copy does not report administering individual gut commensals to mice or testing anti-PD-1 efficacy in those mice. (LLM, conf=0.90)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the indexed copy (section labeled Abstract; no page given), fecal transfer from responding patients improved tumor control in melanoma-bearing mice, and anti–PD-L1 treatment was effective in mice colonized with responder microbiota. The mouse experiment tested anti–PD-L1, not anti–PD-1; the copy also does not show that administering individual commensal species improved checkpoint-treatment efficacy in those mice. (LLM, conf=0.88)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, composition of the gut microbiome modulates therapeutic activity of anti–PD-1 and anti–programmed death-ligand 1 (PD-L1)”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 source
The mouse FMT experiments (Results, Fig. 4G–I passage) state that germ-free mice transplanted with stool from anti–PD-1 responders had significantly reduced tumor growth (p=0.04) versus NR-FMT recipients, and that 'mice transplanted with R-FMT also exhibited improved responses to anti-PD-L1 therapy (Fig. 4I) in contrast to mice that were transplanted with stool from NR (NR-FMT)' — i.e. microbiome composition modulated therapeutic activity of both agents in mice. The abstract likewise reports enhanced anti-tumor immunity 'in germ-free mice receiving fecal transplants from responding patients,' and the closing discussion generalizes to modulation of anti–PD-1 response. The claim's mouse-only scope matches what the paper demonstrates causally in mice. (LLM, conf=0.87)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
Our copy supports the anti–PD-L1 half of the claim with the paper's own in vivo data: in germ-free mice reconstituted with fecal material from responder versus nonresponder patients, 'Anti–PD-L1 was markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice (Fig. 3F)' (Results, Abstract section), and the Abstract states reconstitution with responder feces gave 'greater efficacy of anti-PD-L1 therapy'. However, this study did not administer anti–PD-1 to mice — its patient-level anti–PD-1 association is clinical (42 metastatic melanoma patients), and the mouse evidence for microbiome modulation of anti–PD-1 is explicitly credited to other work: 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)... fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (Discussion). The intro likewise frames the mouse microbiome/anti–PD-L1 precedent as preclinical studies of reference (4). The attribution of the anti–PD-1-in-mice component to this source is therefore not supported by it. (LLM, conf=0.80)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple circulating cytokines and chemokines decreased after FMT in Rs, including CCL2 (MCP1), CXCL8 (IL-8), and IL-18 that have been associated with negative outcomes to anti–PD-1 (32, 33), and IL-12p70 and IFN-γ (Fig. 4A, heatmap).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant alters serum metabolome and cytokines in responders
What the sources say
- Could not verifycites [32] Gok Yavuz B, Sci. Rep 9, 3172 (2019). 30816272 PMC6395633 sourceExperimental — accuracy not yet measured
Our copy of Yavuz et al. (2019) is an in vitro study of cancer-associated fibroblasts educating CD14+ monocytes/macrophages from healthy donors; it contains no FMT cohort, no patient serum cytokine measurements, and no statement about CCL2/MCP-1, CXCL8/IL-8 or IL-18 levels changing after treatment or being associated with anti-PD-1 outcomes. The closest passages are the Results section 'Recruitment of monocytes by CAFs might be mediated by MCP-1 as well as SDF-1 cytokines' (blocking MCP-1 reduced monocyte migration in vitro) and the Discussion on PD-1+ TAMs citing Gordon et al. and Topalian et al., neither of which addresses circulating cytokine change or immunotherapy outcome association. Searched: 'CCL2 MCP-1 CXCL8 IL-18 negative outcomes anti-PD-1' and 'fecal microbiota transplantation responders serum cytokines' — no supporting passage. (LLM, conf=0.75)
- Not checked yetcites [33] Terme M, Cancer Res. 71, 5393– 5399 (2011). 21724589 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
28 more claims
Create a free account to see all 56 claims and to verify the 17 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In two proof-of-concept trials with a total of 26 patients, responder-derived fecal microbiota transplantation (FMT) overcame PD-1 resistance in a third of patients with melanoma, suggesting that microbiome modulation could improve responsiveness to anti-PD-1 ICB10,11.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concurs with another clinical trial with a similar FMT-ICB design in which Akk was also associated with response to ICB post-FMT (Davar et al., 2021).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Davar et al. (2021) found that combining FMT with anti-PD-1 therapy in refractory melanoma patients led to meaningful changes in gut microbial composition, increased activation of CD8+ natural killer-like T cells, recirculation of mucosa-associated invariant T cells, and distinct metabolic shifts associated with enhanced antitumor responses.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of two phase 1 clinical studies NCT03341143 and NCT03353402 showed responder-derived FMT effectively relieved the resistance to α-PD-1/PD-L1 in some melanoma patients, having implications for modulating gut microbiota in cancer immunotherapy [26, 317].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
33 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Cited by
Items 601–700 of 1,002
Gut microbiota – a double-edged sword in cancer immunotherapy
Andrews, M. C., & Vasanthakumar, A. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.003 · Cited by 20
Gut microbiota: a potential target for improved cancer therapy
Zhao, M., Jiang, G., Zhou, H., Li, J., Xiang, W., Li, S., Wang, H., & Zhou, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04546-5 · Cited by 20
Self-citationExploring the roles of intestinal flora in enhanced recovery after surgery
Liu, Z., Li, N., Dang, Q., Liu, L., Wang, L., Li, H., & Han, X. (2023) · iScience · doi:10.1016/j.isci.2023.105959 · Cited by 25
“proposed the first demonstration on the clinical utility of FMT transfer in patients with metastatic melanoma resistant predominantly to immune checkpoint blockade.(105,106) However, the long-term efficacy and stability of FMT remain unknown.”
Skin Cancer Metabolic Profile Assessed by Different Analytical Platforms
Hagyousif, Y. A., Sharaf, B. M., Zenati, R. A., El‐Huneidi, W., Bustanji, Y. K., Abu‐Gharbieh, E., Alqudah, M. A. Y., Giddey, A. D., Abuhelwa, A. Y., Alzoubi, K. H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021604 · Cited by 19
“Additionally, those who responded exhibited higher levels of CD8+ T cell activation, which can fight off cancers caused by altered cells, higher levels of taxa, previously linked to anti-PD-1 responses, and lower levels of myeloid cells, which express interleukin-8, necessary for the survival and proliferation of canc…”
BackgroundOh, M., & Zhang, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-31210-w · Cited by 24
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Leone, G. M., Candido, S., Lavoro, A., Vivarelli, S., Gattuso, G., Călina, D. C., Libra, M., & Falzone, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041252 · Cited by 26
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
“66”
BackgroundMicroecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu, X.-L., Li, S., Ma, K.-X., & Wang, L. (2024) · Biochimica et Biophysica Acta - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167230 · Cited by 20
Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma
Scarpellini, E., Scarlata, G. G. M., Santori, V., Scarcella, M., Kobyliak, N. M., & Abenavoli, L. (2024) · Biomedicines · doi:10.3390/biomedicines12081797 · Cited by 22
Pomej, K., Frick, A. P., Scheiner, B., Balcar, L., Pajancic, L., Klotz, A., Kreuter, A., Lampichler, K., Regnat, K., Zinober, K., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321189 · Cited by 24
“No relevant FMT-related adverse events were reported [16].”
InfluentialHu, M., Zhu, X., Huang, X., Li, H., Lin, X., Zhang, H., Hu, Y., Tong, T., Li, L., Xuan, B., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115589 · Cited by 23
Nutrient acquisition of gut microbiota: Implications for tumor immunity
Wang, Y., Huang, J., Tong, H., Jiang, Y., Yu, J., & Ma, X. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.003 · Cited by 20
Li, W., Xu, M., Cheng, M., Wei, J., Zhu, L., Deng, Y., Guo, F., Bi, F., & Liu, M. (2025) · Cancer Medicine · doi:10.1002/cam4.71065 · Cited by 21
“Clinically, FMT from responders has shown promise in converting PD-1 inhibitor non-responders to responders in some melanoma patients, yielding significant clinical benefits [147].”
DiMaio, D., Emu, B., Goodman, A. L., Mothes, W., & Justice, A. C. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab212 · Cited by 24
Leigh, S., Lynch, C. M. K., Bird, B., Griffin, B. T., Cryan, J. F., & Clarke, G. A. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2043849 · Cited by 19
The Emerging Roles of Human Gut Microbiota in Gastrointestinal Cancer
Guo, Q., Qin, H., Liu, X., Zhang, X., Chen, Z., Qin, T., Chang, L., & Zhang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915047 · Cited by 25
Xu, L., Ma, Y., Fang, C., Peng, Z., Gao, F., Moll, J. M., Qin, S., Yu, Q., Hou, Y., Kristiansen, K., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.953884 · Cited by 21
“Of note, the potential for enhancing cancer immunotherapy by modulating the gut microbiota has been highlighted by two recent clinical trials applying fecal microbiota transplantation (FMT) to melanoma patients that received anti-PD-1 therapy (22, 23).”
BackgroundMicrobiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
Mishra, S., Amatya, S. B., Salmi, S., Koivukangas, V., Karihtala, P., & Reunanen, J. (2022) · Cancers · doi:10.3390/cancers14205121 · Cited by 19
“Failure in response to FMT treatment may be due to various reasons including the inability to replace the host microbiota and successfully implant beneficial microbiota favoring anti-PD-1 treatment into the recipient, the inability to respond to the tumor progression regardless of beneficial microbiota obtained becaus…”
BackgroundInfluentialHot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
Zhang, X., Ishikawa, D., Ohkusa, T., Fukuda, S., & Nagahara, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1068567 · Cited by 19
“FMT has been implemented in a variety of disease fields (9–11), especially in improving the response of anti-PD-1 immunotherapy in metastatic melanoma (12, 13).”
BackgroundConsistent Stool Metagenomic Biomarkers Associated with the Response To Melanoma Immunotherapy
Olekhnovich, E. I., Ivanov, A. B., Babkina, A. A., Sokolov, A. A., Игоревич, У. В., Fedorov, D. E., & Ilina, E. N. (2023) · mSystems · doi:10.1128/msystems.01023-22 · Cited by 21
“Additional data that showed the impact of FMT on immunotherapy (11, 12) were used to validate the identified biomarkers.”
MethodFecal Microbiota Transplantation as a Cancer Therapeutic
Stoff, R., Wolf, Y., & Boursi, B. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000651 · Cited by 23
The human microbiome links to prostate cancer risk and treatment (Review)
Xia, B., Wang, J., Zhang, D., & Hu, X. (2023) · Oncology Reports · doi:10.3892/or.2023.8560 · Cited by 19
“There are also beneficial effects of microbiota on cancer treatment, as confirmed by recent clinical trials on fecal microbiota transplantation (FMT) in combination with immunotherapy for cancer treatment, potentially opening up new targets for cancer treatment (6).”
Vandoni, G., D’Amico, F., Fabbrini, M., Mariani, L., Sieri, S., Casirati, A., Guardo, L. D., Vecchio, M. D., Anichini, A., Mortarini, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411611 · Cited by 18
Microbes mediated immunogenic cell death in cancer immunotherapy
Huang, J., Duan, F., Xie, C., Xu, J., Zhang, Y., Wang, Y., Tang, Y., & Leung, E. L. (2023) · Immunological Reviews · doi:10.1111/imr.13261 · Cited by 20
“34,35 Besides, recent efforts also found that individual microbial species or microbial consortia has the potential to facilitate cancer therapies.”
BackgroundLi, J., Guo, Y., Liu, J., Guo, F., Du, L., Yang, Y. P., Li, X., & Ma, Y. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007420 · Cited by 19
Kamer, O., Rinott, E., Tsaban, G., Kaplan, A., Meir, A. Y., Zelicha, H., Knights, D., Tuohy, K. M., Fava, F., Scholz, M., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2264457 · Cited by 20
“14 Due to the increasing prevalence of obesity, 15 and reports supporting the role of the gut microbiome in obesity, 16–19 FMT has garnered attention as a possible treatment for obesity.”
BackgroundGut microbiome, metabolome and alopecia areata
Liu, Z., & Liu, X. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1281660 · Cited by 25
“…of the gut flora in AA patients (Xie et al., 2019), accumulating clinical evidences support its potential efficacy in treatments of tumors (Davar et al., 2021; Routy et al., 2023), autoimmune diseases (Huang C. et al., 2022), inflammatory bowel diseases (Sokol et al., 2020), especially…”
BackgroundImmune‐related adverse events of antibody‐based biological medicines in cancer therapy
Rajagopal, D., MacLeod, E., Corogeanu, D., & Vessillier, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18470 · Cited by 22
“42,43 Evidence for the influence of gut microbiome composition is supported by the observed poor efficiency of ICI therapy in germ-free preclinical models and patients undergoing antibiotic treatment prior to ICI therapy.”
BackgroundBouferraa, Y., Chedid, A., Amhaz, G., Lakkiss, A. E., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158036 · Cited by 18
Impact of the ileal microbiota on colon cancer
Roberti, M. P., Rauber, C., Kroemer, G., & Zitvogel, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.016 · Cited by 18
‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 20
“Finally, in 2021, the results of two phase I trials demonstrated this recapitulation human-to-human, with responders’ stool reinvigorating anti-PD1 response in a subset of melanoma patients with resistant or refractory tumours [94,95].”
ResultIntegrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome
Khodadoust, M. S., Mou, E., & Kim, Y. H. (2022) · Blood · doi:10.1182/blood.2020008241 · Cited by 22
Unlocking the power of the microbiome for successful cancer immunotherapy
Clavijo-Salomon, M. A., & Trinchieri, G. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011281 · Cited by 18
“11 14 In these two studies, FMT proved safe and effective in addressing dysbiosis and overcoming resistance to ICI, with about 40% response to anti- PD-1 following FMT and at least one patient achieving a complete response in each study.”
Self-citationSusiriwatananont, T., Eiamprapaporn, P., Roque, M. V., Farraye, F. A., Pearlman, A., & Chumsri, S. (2025) · Cells · doi:10.3390/cells14221779 · Cited by 21
“Subsequent proof-of-concept clinical studies in ICI-refractory melanoma patients confirmed that FMT, when combined with re-induction anti-PD1, could overcome ICI resistance in a subgroup of patients by altering the gut microbiome and tumor microenvironment [140,141].”
Zhang, Y., Xu, X., Wang, S., Yin, X., Zhang, B., Zhu, Z., Ji, R., Zhu, J., He, H., Cheng, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013823 · Cited by 30
“10 11 12 However, the efficacy appears to vary significantly by cancer type, as evidenced by a recent study reporting an ORR of only 7.7% in a broader cohort of patients with immunotherapy-refractory solid tumors.”
InfluentialAraji, G., Maamari, J., Ahmad, F. A., Zareef, R. O., Chaftari, P. S., & Yeung, S. J. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-10 · Cited by 22
“Davar et al([105]) similarly conducted an open-label single-armed study that highlighted the improved clinical benefit in PD-1 refractory melanoma patients after responder-derived FMT, with increase in the abundance of taxa associated with a positive response.”
BackgroundDoes the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy?
Lin, Y., Kong, D.-X., & Zhang, Y.-N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852194 · Cited by 17
Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 20
Golčić, M., Simetić, L., Herceg, D., Blažičević, K., Jovanović, G. K., Dražić, I., Belančić, A., Skočibušić, N., Palčevski, D., Rubinić, I., et al. (2023) · Cancers · doi:10.3390/cancers15113052 · Cited by 18
“Furthermore, while various dietary and lifestyle habits, including the use of medications, dietary supplements, and the level of exercise, were found to have a tremendous impact on the gut microbiome [4,5,7,36–38], the majority of trials on this topic, including the pivotal FMT trials [17,18], did not evaluate dietary…”
BackgroundInfluentialWu, X., Pan, L., Wang, W., Xu, J., Ai, R., Wen, Q., Cui, B., & Zhang, F. (2023) · Nutrients · doi:10.3390/nu15153340 · Cited by 19
“FMT and immunotherapy have been re rte t t e t icr i ta a re r ra t e t r icr e ir e t t erc e resista ce t i nothera y in atients ith a vance elano a [10].”
BackgroundInfluentialLiu, G., Huang, W., Chen, L., Tayier, N., You, L., Hamza, M., Tian, X., Wang, H., Nie, G., Zhu, M., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101993 · Cited by 17
Self-citationKou, L., Xie, X., Chen, X., Li, B., Li, J., & Li, Y. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03568-3 · Cited by 19
“Additionally, one clinical trial study found that fecal microorganisms combined with anti-PD-1 treatment could overcome patients' resistance to PD-1 blockers [120].”
BackgroundGut microbiota and immunotherapy of renal cell carcinoma
Bibbò, S., Porcari, S., Vecchio, L. E. D., Severino, A., Mullish, B. H., Ianiro, G., Gasbarrini, A., & Cammarota, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2268982 · Cited by 20
“106 In both trials, patients affected by melanoma and durable responders to anti-PD1 therapy have been used as donors.”
MethodPolyphenolic Compounds: Orchestrating Intestinal Microbiota Harmony during Aging
Pereira, Q. C., Fortunato, I. M., Oliveira, F. D. S., Alvarez, M. C., dos Santos, T. W., & Ribeiro, M. L. (2024) · Nutrients · doi:10.3390/nu16071066 · Cited by 19
Lin, X., Jiao, R., Cui, H., Yan, X., & Zhang, K. (2024) · Advanced Science · doi:10.1002/advs.202403156 · Cited by 26
Cui, L., Xu, X. H., Fan, H., Wan, X., Chen, Q., Zhang, J., Tao, C., Du, Z., Wang, S., Zhang, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217183 · Cited by 19
Davidson, E. A., Monteverde, D. R., & Semrau, J. D. (2024) · Communications Earth & Environment · doi:10.1038/s43247-024-01656-5 · Cited by 19
“Historic and recent developments in medicine and agriculture have demonstrated that human intervention in the microbial content of various environments, ranging from the human gut to agricultural soils, can have bene fi cial impacts 10 – 13 .”
Cesano, A., Augustin, R. C., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008876 · Cited by 25
Self-citationHow gut bacteria could boost cancer treatments
Erdmann, J. M. (2022) · Nature · doi:10.1038/d41586-022-01959-7 · Cited by 18
Zhao, W. (2024) · American Journal of Cancer Research · doi:10.62347/xkuj3012 · Cited by 17
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Shang, J., Valle, D. M. D., Britton, G. J., Mead, K., Rajpal, U., Chen-Liaw, A., Mogno, I., Li, Z., Menon, R., Gonzalez‐Kozlova, E., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232079 · Cited by 17
“This is consistent with previous reports of Bacteroides intestinalis enrichment at baseline in combined ICB-treated patients with metastatic melanoma who eventually developed ≥ grade 3 irAEs (Davar et al., 2021).”
Vigano, M., Wang, L., As’sadiq, A., Samarani, S., Ahmad, A., & Costiniuk, C. T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1497829 · Cited by 19
Malard, F., Thépot, S., Cluzeau, T., Carré, M., Lebon, D., Bories, P., Legrand, O., Schwarz, M., Loschi, M. L., Meunier, M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015571 · Cited by 22
“Fecal microbiotherapy showed promising results, in particular in melanoma patients, where it circumvented primary and secondary immune checkpoint inhibitor resistance, 11,12 but also for the treatment of graft-versus-host disease (GVHD).”
The mechanisms and therapeutic potential of the microbiome-immune interface in cancer
Christina, B., Poongkuzhali, S., Muninathan, N., Bhaskaran, K., & Suresh, A. (2025) · Discover Biotechnology · doi:10.1007/s44340-025-00031-0 · Cited by 18
“In a phase I trial of patients with metastatic melanoma, it was shown that FMT by responders to ICI resulted in greater microbial diversity, greater activation of CD8 + T cells and increased overall response rates [94].”
Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy
Jani, C., Edwards, K., Bhanushali, C. D., Zheng, X. X., Salazar, A. S., Lopes, G. D. L., Jr., & Watson, D. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713382 · Cited by 21
Baaziz, H., Baker, Z. R., Franklin, H. C., & Hsu, B. B. (2022) · iScience · doi:10.1016/j.isci.2022.104146 · Cited by 19
“In instances where gut bacteria can alter drug efficacy, FMTs can reverse this effect 2 iScience 25, 104146, April 15, 2022 as shown with microbiota-associated resistance to anti-PD-1 therapy (Davar et al., 2021).”
BackgroundCheng, X., Wang, J., Gong, L., Dong, Y., Shou, J., Pan, H., Yu, Z., & Fang, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185479 · Cited by 20
“Despite the differing compositions of the fecal microbiome transplants from the donors in these two studies, a subgroup of refractory metastatic melanoma patients (30% (3/10) and 40% (6/15)) demonstrated clinical responses in both studies [24,25].”
BackgroundResultInfluentialAdvanced development of biomarkers for immunotherapy in hepatocellular carcinoma
Peng, X., Gong, C., Zhang, W., & Zhou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1091088 · Cited by 18
Mattiola, I., & Diefenbach, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101724 · Cited by 19
Boicean, A., Bratu, D. G., Bacila, C. I., Tanasescu, C. A. H., Fleacă, R. S., Mohor, C. I., Comaniciu, A., Băluță, T., Roman, M. D., Chicea, R., et al. (2023) · Pathogens · doi:10.3390/pathogens12060766 · Cited by 17
“The conclusion of this study strengthens the importance of commensal microbes in antitumor immunity and the role of FMT in cancer, especially in patients that undergo immunotherapy [53].”
BackgroundFluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
Sarkar, J., Gomez, E. C., Oba, T., Chen, H., Dy, G. K., Segal, B. H., Ernstoff, M. S., & Ito, F. (2023) · World Journal of Oncology · doi:10.14740/wjon1587 · Cited by 20
“The abundance of Bifidobacterium, Coriobacteria, Ruminococcae, Prevotellaceae, and Lachnospiraceae have been linked to good response to ICI therapy [22, 41], while non-responders have been found to have gut microbiome abundance of species such as Bacteroides and Escherichia coli [44].”
BackgroundEfficient Mining of Anticancer Peptides from Gut Metagenome
Ma, Y., Liu, X., Zhang, X., Yu, Y., Li, Y., Song, M., & Wang, J. (2023) · Advanced Science · doi:10.1002/advs.202300107 · Cited by 17
Pang, S. A., Elkrief, A., Capella, M. P., & Miller, W. H. (2023) · Current Oncology · doi:10.3390/curroncol30090570 · Cited by 16
“Promising results were also seen in two published phase I trials (NCT03341143, NCT03353402) evaluating FMT with ICIs administered to ICI-refractory patients [1,5].”
ResultBoicean, A., Bratu, D. G., Fleacă, R. S., Vasile, G., Shelly, L., Bîrsan, S., Bacila, C. I., & Hasegan, A. G. (2023) · Pathogens · doi:10.3390/pathogens12091149 · Cited by 18
“One such approach that has gained attention among IBD researchers is FMT, which has already been successfully used for managing recurrent Clostridioides difficile infection (CDI), with strong recommendations in the treatment guidelines of the United States and Europe for CDI cases [65,66].”
BackgroundLifestyle and host determinants of antitumor immunity and cancer health disparities
Swaby, A. M., Atallah, A., Varol, O., Cristea, A., & Quail, D. F. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.08.007 · Cited by 19
Role of the Microbiota in Skin Neoplasms: New Therapeutic Horizons
Savoia, P., Azzimonti, B., Rolla, R., & Zavattaro, E. (2023) · Microorganisms · doi:10.3390/microorganisms11102386 · Cited by 19
“Recently, a clinical trial evaluated the safety and efficacy of the transplantation of responder-derived fecal microbiota together with anti-PD-1 in a small group of patients affected by PD-1–refractory melanoma [71,72].”
BackgroundWang, J., Liu, X., Sun, R., Mao, H., Liu, M., & Jin, X. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011683 · Cited by 16
Manni, A., Sun, Y., Schell, T. D., Lutsiv, T., Thompson, H. J., Chen, K.-M., Aliaga, C. A., Zhu, J., & El‐Bayoumy, K. (2023) · Pharmaceuticals · doi:10.3390/ph16101422 · Cited by 19
Hoyd, R., Wheeler, C. E., Liu, Y., Singh, M. S. J., Muniak, M., Jin, N. Y., Denko, N. C., Carbone, D. P., Mo, X. M., & Spakowicz, D. J. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0435 · Cited by 16
“Microbes have been shown to affect survival in the context of chemotherapy (27), radiation (26), and immunotherapy (2–4, 28, 29).”
BackgroundKumavath, R., Pavithran, H., Paul, S., Anju, V. T., Busi, S., & Dyavaiah, M. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5592 · Cited by 17
Tang, L., Yang, X., Zhou, M., Feng, L., Ji, C., Liang, J., Zhang, B., Shen, R., & Wang, L. (2024) · mSystems · doi:10.1128/msystems.00138-24 · Cited by 20
“Besides, the gut microbiota was also recognized as essential in regulating tumor immunotherapy in recent years (10–14).”
BackgroundEating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome
Nguyen, N.-T. A., Jiang, Y., & McQuade, J. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1409414 · Cited by 23
Zheng, J., & Chen, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429722 · Cited by 20
Impact of the Lung Microbiota on Development and Progression of Lung Cancer
Belaïd, A., Roméo, B., Rignol, G., Benzaquen, J., Audoin, T., Vouret‐Craviari, V., Brest, P., Varraso, R., von Bergen�, M., Marquette, C., et al. (2024) · Cancers · doi:10.3390/cancers16193342 · Cited by 18
Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota
Green, G. B. H., Cox-Holmes, A. N., Potier, A. C. E., Marlow, G. H., & McFarland, B. C. (2024) · Biomedicines · doi:10.3390/biomedicines12112429 · Cited by 16
Intra-tumoral bacteria in breast cancer and intervention strategies
Hou, T., Huang, X., Lai, J., & Zhou, D. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115516 · Cited by 20
Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Zhang, Y., Mo, C., Ai, P., He, X., Xiao, Q., & Yang, X. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2454937 · Cited by 20
The interplay between gut bacteria and targeted therapies: implications for future cancer treatments
He, J., Chen, Y., Zhao, H., & Li, Y. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01108-6 · Cited by 21
Diop, K., Mbaye, B., Nili, S., Filin, A., Benlaïfaoui, M., Malo, J., Renaud, A. S., Belkaïd, W., Hunter, S., Messaoudene, M., et al. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00694-4 · Cited by 17
“These findings have driven the development of clinical trials aimed at modifying the gut microbiome through various methods, including FMT [9–11].”
The human microbiome: redefining cancer pathogenesis and therapy
Adlakha, Y. K., & Chhabra, R. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03787-x · Cited by 25
“CD8 + T cells are responsible for targeted killing of tumor cells and IL-8 expressing myeloid cells are involved in immunosuppression, which aids the tumor progression [173].”
Koo, H., & Morrow, C. D. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02312-0 · Cited by 16
Pomej, K., Balcar, L., Scheiner, B., Semmler, G., Meischl, T., Mandorfer, M., Reiberger, T., Müller, C., Trauner, M., & Pinter, M. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s317957 · Cited by 17
“In line with this, fecal microbiota transplantation improved the response to reinitiated PD-1-targeted ICIs in immunotherapy-refractory melanoma patients.(21,22) Data suggesting that the gut microbiome affects the outcome of patients with HCC treated with immunotherapy were reported recently.”
ResultHarnessing the microbiome to restore immunotherapy response
Bullman, S., Eggermont, A. M. M., Johnston, C. D., & Zitvogel, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00300-x · Cited by 17
Too much water drowned the miller: Akkermansia determines immunotherapy responses
Li, L., & McAllister, F. M. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100642 · Cited by 21
“2 Cell Reports Medicine 3, 100642, May 17, 2 In conclusion, individual baseline gut microbiota profiling may represent promising biomarkers to predict ICIs responses as well as immune-related adverse effects.(7,10) Understanding and addressing the specific bacteria and roles in contributing to better outcomes should b…”
BackgroundResultEngineered microneedle systems for topical cancer therapy
Jiang, X., Xia, W., Pan, J., Yang, W., Zhang, S., Li, C., Zan, T., Lai, Y., Xu, Z., & Yu, H. (2023) · Applied Materials Today · doi:10.1016/j.apmt.2023.101774 · Cited by 19
Self-citationThe Gut Microbiome Controls Liver Tumors via the Vagus NervePreprint
Bauer, K. C., Trehan, R., Ruf, B., Myojin, Y., Benmebarek, M.-R., Ma, C., Seifert, M., Nur, A., Qi, J., Huang, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.23.576951 · Cited by 20
Self-citationOey, O., Liu, Y.-Y., Sunjaya, A. F., Simadibrata, D. M., Khattak, M. A., & Gray, E. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i11.929 · Cited by 15
Saha, S., Rehman, L., Rehman, A., Darbaniyan, F., Weber, D. M., Becnel, M., Gaballa, M., Thomas, S. K., Lee, H. C., Chang, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014476 · Cited by 16
Ji, S., Ahmad, F., Peng, B., Yang, Y., Su, M., Zhao, X., & Vatanen, T. (2025) · Microbiome · doi:10.1186/s40168-025-02046-5 · Cited by 22
“…including multidrug-resistant bacteria (MDRB) infections [5–7], Crohn’s disease (CD) [8, 9], ulcerative colitis (UC) [5, 10–12], anti-PD-1 therapy-resistant melanoma [13, 14], metabolic syndrome [15], obesity [3], tyrosine kinase inhibitors (TKI)-related diarrhea [16], and Tourette syndrome [17].”
Classic versus innovative strategies for immuno-therapy in pancreatic cancer
Formelli, M. G., Palloni, A., Tavolari, S., Deiana, C., Andrini, E., Marco, M. D., Campana, D., Lamberti, G., & Brandi, G. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115671 · Cited by 20
Zhao, C., Li, S.-S., Yau, T. C. C., Chen, W., Ren, J., Guan, X., & Kong, F. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102370 · Cited by 19
“10,11 However, its role in modulating immuno-therapy responses in HCC remains poorly understood.”
Lauricella, S., Brucchi, F., Cirocchi, R., Cassini, D., & Vitellaro, M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15110552 · Cited by 20
Cui, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112923 · Cited by 15
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
Li, Y., Wang, S., Lin, M., Hou, C., Li, C., & Li, G. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0927-0 · Cited by 15
Co-dependencies in the tumor immune microenvironment
Chen, P., & Dey, P. (2022) · Oncogene · doi:10.1038/s41388-022-02406-7 · Cited by 15
“Further, the use of FMT, where stool from healthy or ICI responder patients is transferred to non-responder patients to improve ICI response [144].”
MethodThe Microbiome in PDAC—Vantage Point for Future Therapies?
Pfisterer, N., Lingens, C., Heuer, C., Dang, L., Neeße, A., & Ammer‐Herrmenau, C. (2022) · Cancers · doi:10.3390/cancers14235974 · Cited by 15
“Here, three out of ten patients and six out of fifteen patients showed a clinical response, respectively [98,99].”
BackgroundReal world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
Stoff, R., Asher, N., Laks, S., Steinberg‐Silman, Y., Schachter, J., Shapira‐Frommer, R., Grynberg, S., & Ben‐Betzalel, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1180988 · Cited by 17
“The median follow-up time was 6 months (1-25).”
BackgroundIntestinal microbiota: A bridge between intermittent fasting and tumors
Liu, J., Shao, N., Qiu, H., Zhao, J., Chen, C., Wan, J., He, Z., Zhao, X., & Xu, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115484 · Cited by 17
Tsunedomi, R., Shindo, Y., Nakajima, M., Yoshimura, K., & Nagano, H. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2281482 · Cited by 15
“The usefulness of altering the host-tumor relationship by FMT, in which specific fecal bacteria are transferred into the patient’s gut via an endoscope or oral capsule, has been reported for various solid tumors [100].”
BackgroundMechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC
Liu, T., Guo, Y., Liao, Y., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1333864 · Cited by 16
Metadata
- Authors
- Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A. A., Schwartz, M. B., Dubner, H. M., Ernst, S. J., Rose, A., Najjar, Y. G., Belkaid, Y., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M.
- Affiliations
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
- Oregon State University (US)
- National Institutes of Health (US)
- Corresponding author
- Davar, Diwakar
- Dzutsev, Amiran K.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- ORCID
- Davar, Diwakar
- Dzutsev, Amiran K.
- McCulloch, John A.
- Rodrigues, Richard R.
- Chauvin, Joe-Marc
- Morrison, Robert M.
- Pagliano, Ornella
- Zidi, Bochra
- Zhang, Shuowen
- Badger, Jonathan H.
- Vetizou, Marie
- Cole, Alicia M.
- Fernandes, Miriam R.
- Prescott, Stephanie
- Costa, Raquel G. F.
- Balaji, Ascharya K.
- Morgun, Andrey
- Vujkovic-Cvijin, Ivan
- Wang, Hong
- Borhani, Amir A.
- Schwartz, Marc B.
- Dubner, Howard M.
- Najjar, Yana G.
- Belkaid, Yasmine
- Kirkwood, John M.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 595-602
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8097968
- OpenAlex
- W3126208996
- Cited by
- 1,781
- References
- 54
- Citations by year
- 2026: 396 · 2025: 328 · 2024: 315 · 2023: 316 · 2022: 282 · 2021: 141
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA228181, CA222203)
- Melanoma Research Foundation (MRFBC 2020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, melanoma, immunotherapy resistance, gut microbiota, CD8+ T cell activation, interleukin-8, myeloid cells, immunosuppression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Humans, Lymphocyte Activation, Melanoma, Skin Neoplasms, Interleukin-8, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Myeloid Cells, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.